§ 314.100. Timeframes for reviewing applications and abbreviated applications.
140 words·~1 min read·
/us/cfr/t21/s§ 314.100·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Except as provided in paragraph
(c)of this section, within 180 days of receipt of an application for a new drug under section 505(b) of the act or an abbreviated application for a new drug under section 505(j) of the act, FDA will review it and send the applicant either an approval letter under § 314.105 or a complete response letter under § 314.110. This 180-day period is called the “initial review cycle.”
(b)At any time before approval, an applicant may withdraw an application under § 314.65 or an abbreviated application under § 314.99 and later submit it again for consideration.
(c)The initial review cycle may be adjusted by mutual agreement between FDA and an applicant or as provided in §§ 314.60 and 314.96, as the result of a major amendment. [73 FR 39609, July 10, 2008]
Connections2 cite this
Cited by 2 sections
Citation graph
cites case law
§ 314.100
Timeframes for reviewing applications and abbreviated applications.
Fed. Reg.×2
Cites 0Cited by 2 across 1 source